Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.
暂无分享，去创建一个
Matthew J. Oborski | F. Toledo | J. Mountz | A. Tolcher | M. Lotze | G. Weiss | K. Papadopoulos | M. Beeram | D. Rasco | A. Patnaik | M. Jeffers | L. Appleman | P. Rajagopalan | René J Alvarez | R. Ramanathan | R. Dubowy | D. Roth